July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018

Mid and long-term outcomes of viscodilation associated with trabeculotomy using the VISCO360 microinvasive device for the treatment of Open Angle Glaucoma
Author Affiliations & Notes
  • Gabriele Vizzari
    Ophthalmology, Hospital of Legnago, Verona, Italy
  • PAOLO BORDIN
    Ophthalmology, Hospital of Legnago, Verona, Italy
  • Footnotes
    Commercial Relationships   Gabriele Vizzari, None; PAOLO BORDIN, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2058. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gabriele Vizzari, PAOLO BORDIN;
      Mid and long-term outcomes of viscodilation associated with trabeculotomy using the VISCO360 microinvasive device for the treatment of Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2058.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
The purpose of the study was to evaluate the mid and long-term effectiveness and safety profile of viscodilation associated with trabeculotomy in patients with open angle glaucoma operated upon using the VISCO360 microinvasive "ab interno" device (Sight Sciences, Menlo Park, CA).

Methods :
A total of 55 eyes from 37 glaucomatous patients were enrolled in a consecutive interventional noncomparative case series. All the patients were treated with a 360° viscodilation and 100° superior trabeculotomy, using VISCO360 device and Healon GV as viscoelastic substance. Intraocular pressure (IOP), the number of medications, the complications, and the postoperative interventions were reported both preoperatively and during the follow-up. Postoperative IOP and the rate of complications were the primary outcome measures. The complete and qualified surgical success was the secondary endpoint.

Results :
VISCO360 obtained a mean IOP reduction from 20.61±1.62 mmHg (baseline) to 16.09±2.11 mmHg after a mean follow-up period of 14.6±2.3 months. The mean number of medications reduced between preoperative (n=2.52±0.75) and postoperative period (n=0.66±0.94) (P<0.001). Cumulative probability of maintaining an IOP between 15 and 21mmHg and/or a 20% or greater reduction in IOP was 72% at 1 year. Postoperative laser trabeculoplasty (SLT) were required in 8 eyes (15%) in order to further reduce the IOP with either no use or minimal use of postoperative drops. Only 7 patients (13%) presented with hypoema (<2 mm) at the day 1 after surgery, reabsorbed spontaneously within 5 days. No other surgical complications were encountered.

Conclusions :
This technique achieved a high percentage of surgical success during the whole follow-up time and was effective in preventing the most serious immediate complications of other most invasive surgeries.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×